Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05890638
Other study ID # NEU-02.22
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 25, 2023
Est. completion date March 6, 2024

Study information

Verified date September 2023
Source Neutec Ar-Ge San ve Tic A.S
Contact Neutec RD
Email iremkaraman@neutecrdc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the acute bronchodilator effect of the Ipratropium / Levosalbutamol 1.25 mg & 0.5 mg / 2.5 mL fixed dose combination nebuliser solution or Levosalbutamol 1.25 mg / 3 mL nebuliser solution and Ipratropium 500 mcg nebuliser solution in stable moderate-severe-very severe COPD patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 74
Est. completion date March 6, 2024
Est. primary completion date February 6, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Male or female patients aged 40 years and older who have been newly diagnosed or followed up with a diagnosis of COPD. - Stable moderate-severe-very severe COPD patients with a post-bronchodilator FEV1/FVC ratio <70% and a postbronchodilator FEV1 value <80% at the screening visit will be included in the study. - Symptom status such as chronic cough, sputum production, and progressive dyspnea with the BCSS (Breathlessness, Cough and Sputum Scale) Index will be evaluated, and the COPD staging of the patient with CAT (COPD Assessment Test) and the severity of dyspnea with mMRC (Modified Medical Research Council) will be determined. - Patients with at least 10 pack/year smoking status or smoking history (patients who have quit smoking for at least 6 months or more are defined as ex-smokers). - Patients who have not experienced an exacerbation in the previous 4 weeks. - If the study participant is female; women using appropriate contraception (pregnancy test will be performed at screening visit). - Patients with the ability to communicate with the investigator. - Patients who accept to comply with the protocol. - Patients who sign written informed consent form. Exclusion Criteria: - History of hypersensitivity to anticholinergics or SABAs (short acting beta agonist). - History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 3 days prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit. - Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit. - SGOT (serum glutamic-oxaloacetic transaminase) >80 IU/L, SGPT (serum glutamic-pyruvic transaminase) >80 IU/L, bilirubin >2.0 mg/dL or creatinine >2.0 mg/dL. - History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study. - Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit - Recent (within =3 months prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment. - Regularly use of daytime CPAP (continuous positive airway pressure) oxygen therapy for longer than 1 hour per day. - Initiation of pulmonary rehabilitation within the 3 months prior the screening visit. - History of lung volume reduction surgery - Drug or alcohol abuse - Presence of active tuberculosis - History of atopy or allergic rhinitis - Presence of active cancer - Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period - Pregnancy or lactation - Presence of known symptomatic prostatic hypertrophy requiring treatment - Presence of known narrow-angle glaucoma requiring treatment - Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ipratropium / Levosalbutamol Fixed Dose Combination
New combination test treatment
Ipratropium + Levosalbutamol Free Dose Combination
Free combination control treatment

Locations

Country Name City State
Turkey Yedikule Chest Diseases And Thoracic Surgery Training And Reseaerch Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Neutec Ar-Ge San ve Tic A.S

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary FEV1 area under the curve from 0-8 h (FEV1 AUC0-8 h) Change From Baseline in Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC) 0-8h. 8 hours
Secondary FEV1 area under the curve from 0-4 h (FEV1 AUC0-4 h) Change From Baseline in FEV1 AUC (0-4h). 4 hours
Secondary FEV1 AUC4-6 h Change From Baseline in FEV1 AUC (4-6h). 4 to 6 hours
Secondary FEV1 AUC6-8 h Change From Baseline in FEV1 AUC (6-8h). 6 to 8 hours
Secondary FVC AUC0-4 h Change From Baseline in Forced Vital Capacity (FVC) AUC (0-4h). 4 hours
Secondary FVC AUC4-6 h Change From Baseline in FVC AUC (4-6h). 4 to 6 hours
Secondary FVC AUC6-8 sa Change From Baseline in FVC AUC (6-8h). 6 to 8 hours
Secondary FVC AUC0-8 sa Change From Baseline in FVC AUC (0-8h). 8 hours
Secondary Change From Baseline in FEV1 and FVC within the first 15 minutes after dosing Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated. Baseline, 15 minutes post-dose at treatment day.
Secondary Mean Maximum Change From Baseline in FEV1 and FVC within the first 2 hours after dosing Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration. The measurements at the time points related to the outcome will be evaluated. Baseline, 2 hours post-dose at treatment day
Secondary Mean Maximum Change From Baseline in FEV1 and FVC over a period of 8 hours Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration. Baseline, 0 to 8 hours post-dose at treatment day
Secondary The Time to Onset of Bronchodilator Response Bronchodilator response is defined as 100 mL improvement in FEV1. Baseline, 0 to 8 hours post-dose at treatment day
Secondary Evaluation of Safety Number of participants with Adverse Events, with abnormal physical examinations, abnormal laboratory test results and abnormal ECGs Baseline, 0 to 24 hours post-dose
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A